ArticleJournal of translational medicine2025
Whole‑exome evolutionary profiling of osteosarcoma uncovers metastasis‑related driver mutations and generates an independently validated predictive classifier.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- Recent advances in targeting the cGAS-STING pathway for immunotherapy in orthopedic diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteosarcoma is the most common primary malignant bone tumor, with high invasiveness and metastatic potential and a poor prognosis in patients with metastatic cancer. Despite the rapid advancements in genomics in recent years that provided new perspectives for studying the molecular mechanisms of osteosarcoma, the understanding of its tumor heterogeneity and evolutionary mutation process remains limited.
methodsIn this study, whole-exome evolutionary profiling was performed on data from the TARGET database representing 61 osteosarcoma cases. Subclonal architectures were reconstructed to characterize mutational trajectories. Differential mutation analysis was used to identify candidate metastasis-associated mutations. These features were used to build a metastasis-prediction classifier, which was cross-validated and tested on an independent external cohort. Finally, Suppes' probabilistic theory of causality was integrated with cohort data to infer high-frequency evolutionary paths linked to metastasis.
resultsA linear evolutionary trajectory was observed in 62% of patients, indicating sequential clonal expansion. Eight key mutations were closely associated with metastatic progression. The classifier achieved 83% accuracy in cross-validation and maintained robust performance on the external validation set. Through causal inference, distinct evolutionary routes underpinning metastasis were uncovered, with ATRX mutations frequently occurring as early events that reshaped clonal dynamics and facilitated tumor spread.
conclusionsIn this study, the dynamic evolutionary landscape of osteosarcoma metastasis was delineated, an early metastasis classification model was constructed, and the impact of early clonal ATRX mutations on metastasis initiation were highlighted. These findings offer potential avenues for the early diagnosis and risk assessment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.